Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43845   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-001325-33
    Sponsor's Protocol Code Number:CELLIMIN
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2015-03-03
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2014-001325-33
    A.3Full title of the trial
    Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation
    Evaluación prospectiva de la alorrespuesta celular donante-especifica, para
    la minimización inmunosupresora en el trasplante renal
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Individual assessment for Immunosuppression Minimization in transplanted patients.
    Evaluación individual de la minimización de la inmunosupresión en
    pacientes transplantados.
    A.3.2Name or abbreviated title of the trial where available
    CELLIMIN
    CELLIMIN
    A.4.1Sponsor's protocol code numberCELLIMIN
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCharité - Universitätsmedizin Berlin
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBiodrim Consortium
    B.4.2CountryEuropean Union
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCharité - Universitätsmedizin Berlin
    B.5.2Functional name of contact pointProject manager
    B.5.3 Address:
    B.5.3.1Street AddressAugustenburger Platz 1
    B.5.3.2Town/ cityBerlin
    B.5.3.3Post code13353
    B.5.3.4CountryGermany
    B.5.4Telephone number+34932607385
    B.5.5Fax number+34932607607
    B.5.6E-mailpetra.reinke@charite.de
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTACROLIMUS
    D.3.9.1CAS number 104987-11-3
    D.3.9.2Current sponsor codeTacrolimus
    D.3.9.3Other descriptive nameTacrolimus
    D.3.9.4EV Substance CodeSUB10797MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number0.5 to 5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNmycophenolate mofetil
    D.3.9.1CAS number 128794-94-5
    D.3.9.2Current sponsor codemycophenolate mofetil
    D.3.9.3Other descriptive nameMYCOPHENOLATE MOFETIL
    D.3.9.4EV Substance CodeSUB03360MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number250 to 500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePrednisolone
    D.3.4Pharmaceutical form Suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntraarticular use
    Intramuscular use
    Periarticular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPrednisolone
    D.3.9.2Current sponsor codePrednisolone
    D.3.9.3Other descriptive namePREDNISOLONE
    D.3.9.4EV Substance CodeSUB10018MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    kidney transplant patients
    PACIENTES TRANSPLANTADOS RENALES
    E.1.1.1Medical condition in easily understood language
    kidney transplant patients
    PACIENTES TRANSPLANTADOS RENALES
    E.1.1.2Therapeutic area Body processes [G] - Immune system processes [G12]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The main objective of the study is to demonstrate the utility and safety of the IFN-? ELISPOT marker for the stratification of kidney transplant recipients into low and high IS regimens. The enrichment study will test non-inferiority of low IS regimen compared to high IS regimen, assuming 10% of BPAR at 6-months in the control group, and allowing a non-inferiority limit of maximum 15%.
    EL OBJETIVO PRINCIPAL DEL ENSAYO ES DEMOSTRAR LA UTILIDAD Y
    SEGURIDAD DEL MARCADOR IFN-? ELISPOT PARA LA ESTRATIFICACIÓN
    DE LOS PACIENTES TRANSPLANTADOS RENALES A RECIBIR UN REGIMEN
    INMUNOSUPRESOR MÁS INTESNSO O MÁS SUAVE.EL ESTUDIO PROBARÁ
    LA NO INFERIORIDAD DEL TRATAMIENTO MÁS SUAVE EN COMPARACIÓN
    CON EL TRATAMIENTO MÁS INTENSO, ASUMIENDO UN 10% DE RECHAZO
    AGUDO PROBADO MEDIANTE BIOPSIA RENAL EN EL BRAZO CONTROL Y
    PERMITIENDO UN LÍMITE DE NO INFERIORIDAD MÁXIMO DEL 15%.
    E.2.2Secondary objectives of the trial
    - To investigate differences across treatment arms in the following secondary outcomes:
    e.g. eGFR (ml/min) at 6 and 12 months etc.
    - Health economics, H-R QoL and treatment cost (cost/benefit) at 1, 3, 6, 12 and 24 months.
    - INVESTIGAR LAS DIFERENCIAS ENTRE LOS BRAZOS DE TRATAMIENTO
    EN RELACIÓN A LOS OBJETIVOS SECUNDARIOS.
    - ANÁLISIS DE COSTE BENEFÍCIO Y DE CALIDAD DE VIDA A LOS 1, 3, 6,
    12 Y 24 MESES POST TR.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1) Men and women, age ?18 years.
    2) Subject must be a recipient of a first renal transplant from a deceased or living donor.
    3) Subject must have a current documented PRA <20% and no detectable anti-class I and II HLA antibodies by solid phase assay (Luminex®).
    4) Subject is willing to provide signed written informed consent.
    5) Women of Childbearing Potential (WOCBP) must be using a highly effective method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea ? 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL]. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of clinical trial.
    1) HOMBRES Y MUJERES, EDAD>18 AÑOS.
    2) RECEPTORES DE UN PRIMER TRANSPLANTE RENAR DE UN DONANTE
    VIVO O CADAVER.
    3) EL SUJETO DEBE TENER UN PRA ACTUAL Y DOCUMENTADO <20% Y
    NO PRESENTAR ANTICUERPOS ANTI HLA CLASE I Y/O CLASE II
    MEDIANTE ENSAYO EN FASE SÓLIDA (LUMINEX).
    4) EL SUJETO DEBE PROPORCIONAR SU CONSENTIMIENTO DE FORMA
    ESCRITA
    5) LAS MUJERES EN EDAD FÉRTIL DEBEN UTILIZAR UN MÉTODO
    ANTICONCEPTIVO ÁLTAMENTE EFECTIVO PARA EVITAR EL EMBARAZO
    DURANTE TODO EL ENSAYO
    E.4Principal exclusion criteria
    1) Subjects undergoing renal transplant with a current documented PRA >20% and/or detectable anti-class I and II HLA antibodies by solid phase assay (Luminex®).
    2) CDC positive cross match.
    3) Subjects receiving an allograft from a donor older than 65 years with elevated creatinine levels and/or treated diabetes.
    4) Cold ischemia time (CIT) higher than 24h.
    5) Subjects with a prior solid organ transplant (SOT), including renal re-transplantation, or receiving a concurrent SOT.
    6) Patients previously treated with daclizumab or basiliximab.
    7) Subjects with underlying renal disease of:
    a. Primary focal segmental glomerulosclerosis.
    b. Type I or II membranoproliferative glomerulonephritis
    c. Atypical Haemolytic uremic syndrome (HUS) / thrombotic thrombocytopenic purpura syndrome.
    8) Subject with Hepatitis B chronic infection and/or active infection by Hepatitis C virus (positive PCR result) at the moment of transplant.
    9) Subjects with known human immunodeficiency virus (HIV) infection.
    10) Patients with active systemic infection that requires the continued use of antibiotics.
    11) Patients with neoplasia except localized skin cancer receiving appropriate treatment.
    12) Patients with severe anemia (hemoglobin < 6g/dl), leucopenia (WBC <2500/mm3), thrombocytopenia (platelets <80.000/mm3).
    13) Hemodynamically instable patients even if their hemoglobin level counts > 6 g/dl.
    14) Patients with intestinal pathology or severe diarrhoea that can hinder absorption according to medical criteria.
    15) Subjects with a known hyper sensibility to any of the drugs used in this protocol.
    16) Subjects who have used any investigational drug within 30 days prior to enrolment in this clinical trial.
    17) WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period, women who are pregnant or breastfeeding or women with a positive pregnancy test on enrolment.
    18) Subjects who are legally detained in an official institution
    1) sujetos sometidos a trasplante renal con un PRA> 20% y/o
    anticuerpos anti-clase I y II de HLA detectables mediante un ensayo de
    fase sólida (Luminex®).
    2) CDC prueba cruzada positiva.
    3) Sujetos que recibieron un aloinjerto de un donante mayor de 65 años,
    con niveles elevados de creatinina y/o diabetes tratada.
    4) Tiempo de isquemia fría (CIT) superior a 24h.
    5) Sujetos con un trasplante de órgano sólido anterior (SOT), incluyendo
    re-trasplante renal, o recibir un SOT concurrente.
    6) Pacientes previamente tratados con daclizumab o basiliximab.
    7) Sujetos con enfermedad renal subyacente de:
    a. Glomeruloesclerosis focal y segmentaria primaria.
    b. Tipo I o II glomerulonefritis membranoproliferativa
    c. Síndrome hemolítico urémico atípico (SUH) / síndrome de púrpura
    trombocitopénica trombótica.
    8) Pacientes con hepatitis B crónica y/o infección activa por el virus de
    la hepatitis C (PCR resultado positivo) en el momento del trasplante.
    9) Sujetos con infección conocida por el virus de la inmunodeficiencia
    humana (VIH).
    10) Pacientes con infección sistémica activa que requiera el uso continuo
    de antibióticos.
    11) Pacientes con neoplasia excepto el cáncer de piel localizada que
    reciben un tratamiento adecuado.
    12) Pacientes con anemia grave (hemoglobina <6 g / dl), leucopenia
    (leucocitos <2.500 / mm3), trombocitopenia (plaquetas <80.000 /
    mm3).
    13) Pacientes hemodinámicamente inestables incluso si sus recuentos
    de nivel de hemoglobina> 6 g / dl.
    14) Pacientes con patología intestinal o diarrea severa que puede
    dificultar la absorción según criterio médico.
    15) Pacientes con una hipersensibilidad conocida a cualquiera de los
    fármacos utilizados en este protocolo.
    16) Sujetos que han utilizado cualquier fármaco en investigación en los
    30 días anteriores a la inscripción en este ensayo clínico.
    17) Mujeres potencialmente fértiles que no están dispuestas o no
    pueden utilizar un método aceptable para evitar el embarazo durante
    todo el periodo de estudio, las mujeres que están embarazadas o
    lactantes o con una prueba de embarazo positiva.
    18) Los sujetos que están legalmente detenidos en una institución oficial
    E.5 End points
    E.5.1Primary end point(s)
    The main objective of the study is to demonstrate the utility and safety of the IFN-? ELISPOT marker for the stratification of kidney transplant recipients into low and high IS regimens. The enrichment study will test non-inferiority of low IS regimen compared to high IS regimen, assuming 10% of BPAR at 6-months in the control group, and allowing a non-inferiority limit of maximum 15%.
    EL OBJETIVO PRINCIPAL DEL ENSAYO ES DEMOSTRAR LA UTILIDAD Y
    SEGURIDAD DEL MARCADOR IFN-? ELISPOT PARA LA ESTRATIFICACIÓN
    DE LOS PACIENTES TRANSPLANTADOS RENALES A RECIBIR UN REGIMEN
    INMUNOSUPRESOR MÁS INTESNSO O MÁS SUAVE.EL ESTUDIO PROBARÁ
    LA NO INFERIORIDAD DEL TRATAMIENTO MÁS SUAVE EN COMPARACIÓN
    CON EL TRATAMIENTO MÁS INTENSO, ASUMIENDO UN 10% DE RECHAZO
    AGUDO PROBADO MEDIANTE BIOPSIA RENAL EN EL BRAZO CONTROL Y
    PERMITIENDO UN LÍMITE DE NO INFERIORIDAD MÁXIMO DEL 15%.
    E.5.1.1Timepoint(s) of evaluation of this end point
    12 months post-transplantation
    12 meses post transplante renal
    E.5.2Secondary end point(s)
    To investigate differences across treatment arms in the following secondary outcomes:
    - eGFR (ml/min) assessed by the CKD-EPI formula at 6 and 12 months
    - Prevalence of biomarkers* of tolerance/hyporesponsiveness at 3 and 12 months.
    - Incidence, type, severity, treatment, and outcome of BPAR by 6 and 12 months after transplantation.
    - Prevalence, type, severity, treatment, and outcome of subclinical rejection by 6 and 12 months after transplantation.
    - Prevalence of death, and graft loss by 6 and 12 months.
    - Prevalence of metabolic and cardiovascular co-morbidity (new onset diabetes mellitus (NODAT), dyslipidemias, hypertension) by 12 months.
    - Prevalence of subjects that remain MMF and steroid-free at 6 and 12 months after transplantation
    - Prevalence of Acute and chronic histologic lesions assessed by the Bannf?11 score in protocol biopsies at months 3 and 12 post-transplantation.
    - Prevalence of patients that remain on Therapy at 12 months after transplantation.
    - Distribution of patients in distinct chronic kidney diseases (CKD) stages by 12 months.
    - Health economics, H-R QoL and treatment cost (cost/benefit) at 1, 3, 6, 12 and 24 months.
    Investigar las diferencias entre los grupos de tratamiento en los
    siguientes objetivos secundarios:
    - FGe (ml / min) evaluada por la fórmula CKD-EPI a los 6 y 12 meses
    - Prevalencia de biomarcadores * de tolerancia / respuesta menor a los
    3 y 12 meses.
    - Incidencia, tipo, gravedad, tratamiento y resultado de BPAR a los 6 y
    12 meses después del trasplante.
    - Prevalencia, tipo, gravedad, tratamiento y resultado del rechazo
    subclínico a los 6 y 12 meses después del trasplante.
    - Prevalencia de la muerte, y la pérdida del injerto a los 6 y 12 meses.
    - La prevalencia de alteraciones metabólicas y cardiovasculares,
    comorbilidad (diabetes mellitus nueva aparición (NODAT), dislipidemias,
    hipertensión) a los 12 meses.
    - Prevalencia de los sujetos que permanecen MMF y libre de esteroides a
    los 6 y 12 meses después del trasplante
    - Prevalencia de lesiones agudas y lesiones histológicas crónicas
    evaluadas por la puntuación Bannf'11 en biopsias de protocolo en los
    meses 3 y 12 post-trasplante.
    -Prevalencia de pacientes que permanecen en terapia a los 12 meses
    después del trasplante.
    - Distribución de los pacientes en distintas enfermedades crónicas del
    riñón (CKD) etapas por 12 meses.
    - Economía de la salud, de recursos humanos y la calidad de vida-coste
    del tratamiento (coste / beneficio) a los 1, 3, 6, 12 y 24 meses.
    E.5.2.1Timepoint(s) of evaluation of this end point
    - eGFR (ml/min) assessed by the CKD-EPI formula at 6 and 12 months
    - Prevalence of biomarkers* of tolerance/hyporesponsiveness at 3 and 12 months.
    - Incidence, type, severity, treatment, and outcome of BPAR by 6 and 12 months after transplantation.
    - Prevalence, type, severity, treatment, and outcome of subclinical rejection by 6 and 12 months after transplantation.
    - Prevalence of death, and graft loss by 6 and 12 months.
    - FGe (ml / min) evaluada por la fórmula CKD-EPI a los 6 y 12 meses
    - Prevalencia de biomarcadores * de tolerancia / respuesta menor a los
    3 y 12 meses.
    - Incidencia, tipo, gravedad, tratamiento y resultado de BPAR por 6 y 12
    meses después del trasplante.
    - Prevalencia, tipo, gravedad, tratamiento y resultado del rechazo
    subclínico por 6 y 12 meses después del trasplante.
    - Prevalencia de la muerte, y la pérdida del injerto a los 6 y 12 meses.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic Yes
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA7
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 447
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 222
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state100
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 569
    F.4.2.2In the whole clinical trial 669
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After completing all the protocol treatment and visits, patients will continue with regular visits according to usual practice of the transplant centre.
    In the case of patients with changes in immunosuppressive therapy but with functional graft, study procedures will be performed, at the same time schedules that the patients per protocol.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-05-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-05-21
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-10-31
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 07:59:19 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA